NuScale's Revenue Collapses to $75,000 as Stock Loses 83% from High

What happened

NuScale's stock has collapsed from its 52-week high of $57.42 last October to about $9.50, reflecting a brutal reassessment of its commercial timeline. The company reported second-quarter revenue of just $75,000, down from $8.1 million a year earlier, as prior engineering work wound down and no new binding contracts emerged. Despite holding a unique NRC-approved small modular reactor design and $1.9 billion in cash, NuScale still lacks a single definitive power purchase agreement or module delivery contract, while its key TVA partnership remains non-binding and Romania's financing has stalled. Heavy dilution has compounded the damage: share count rose 29% in the first half of 2026 alone, and insider Fluor Corporation exited its entire position in April. With operating losses running at $121 million in the first half and no revenue base, the stock's value now hinges entirely on future contract conversion rather than current fundamentals.

Implication

The near collapse reflects market realization that regulatory approval is not equivalent to commercial success. With revenue near zero and cash burn high, the company's $2.9 billion market cap is supported only by hope for future nuclear demand. The next six to nine months are critical: a definitive TVA power purchase agreement or Romania pre-EPC contract could re-rate the stock toward the $13 bull case, but absence of such progress would likely push it toward the $7 bear case or lower. Given the heavy insider selling and continued dilution risk, even the $8 attractive entry level from earlier analysis now appears too optimistic. We maintain a WAIT rating but lower our conviction, and would only consider exposure after a binding contract is announced, with position sizing appropriate for a speculative venture-stage company.

Thesis delta

The thesis has weakened further as revenue evaporated to $75,000 in Q2 and no binding contracts have materialized. The previous WAIT rating was based on potential triggers; now the probability of a near-term commercial breakthrough has declined, pushing the fair value range lower within the $8-$13 band. The attractive entry level of $8 now seems less attractive given the deteriorating fundamentals and insider exits, so we lower conviction and would require a binding PPA or pre-EPC contract before re-engaging.